User Manual Privacy Policy Disclaimer Contact us
  Advanced SearchBrowse




Journal Article

Molecular Regulation of Toll-like Receptors in Asthma and COPD


Lucas,  Kurt
Multiphase Chemistry, Max Planck Institute for Chemistry, Max Planck Society;

External Ressource
No external resources are shared
Fulltext (public)
There are no public fulltexts stored in PuRe
Supplementary Material (public)
There is no public supplementary material available

Zuo, L., Lucas, K., Fortuna, C. A., Chuang, C.-C., & Best, T. M. (2015). Molecular Regulation of Toll-like Receptors in Asthma and COPD. Frontiers in Physiology, 6: 312. doi:10.3389/fphys.2015.00312.

Cite as: http://hdl.handle.net/11858/00-001M-0000-0029-D5DE-9
Asthma and chronic obstructive pulmonary disease (COPD) have both been historically associated with significant morbidity and financial burden. These diseases can be induced by several exogenous factors, such as pathogen associated molecular patterns (PAMPs) (e.g., allergens and microbes). Endogenous factors, including reactive oxygen species, and damage-associated molecular patterns (DAMPs) recognized by toll-like receptors (TLRs), can also result in airway inflammation. Asthma is characterized by the dominant presence of eosinophils, mast cells, and clusters of differentiation (CD)4(+) T cells in the airways, while CORD typically results in the excessive formation of neutrophils, macrophages, and CD8+ T cells in the airways. In both asthma and CORD, in the respiratory tract, TLRs are the primary proteins of interest associated with the innate and adaptive immune responses; hence, multiple treatment options targeting TLRs are being explored in an effort to reduce the severity of the symptoms of these disorders. TLR-mediated pathways for both CORD and asthma have their similarities and differences with regards to cell types and the pro inflammatory cytotoxins present in the airway. Because of the complex TLR cascade, a variety of treatments have been used to minimize airway hypersensitivity and promote bronchodilation. Although unsuccessful at completely alleviating CORD and severe asthmatic symptoms, new studies are focused on possible targets within the TLR cascade to ameliorate airway inflammation.